Literature DB >> 27933472

Tumor Necrosis Factor Alpha Inhibitors Did Not Influence Postoperative Morbidity After Elective Surgical Resections in Crohn's Disease.

Paulo Gustavo Kotze1, Mansur Paulo Saab2, Bárbara Saab2, Lorete Maria da Silva Kotze2, Marcia Olandoski3, Lilian Vital Pinheiro4, Carlos Augusto Real Martinez4, Maria de Lourdes Setsuko Ayrizono4, Daniela de Oliveira Magro4, Claudio Saddy Rodrigues Coy4.   

Abstract

BACKGROUND: The real impact of anti-tumor necrosis alpha (TNF) therapy in postoperative complications after intestinal resections in Crohn's disease (CD) still needs to be determined. AIMS: To compare the postoperative complication rates after elective intestinal resections in CD patients, with or without previous exposure to anti-TNF therapy.
METHODS: This was a retrospective and observational study, with elective intestinal resections for CD (emergency procedures were excluded). Patients were allocated in two groups according to preoperative anti-TNF status. Surgical and medical complications were analyzed and subsequently compared between the groups.
RESULTS: A total of 123 patients were included (71 with and 52 without preoperative anti-TNF). The groups were considered homogeneous, except for perianal CD, previous azathioprine, and stomas. There was no significant difference between the groups regarding overall surgical complications (32.69% in anti-TNF- vs. 39.44% in anti-TNFpatients, p = 0.457) or overall medical complications (21.15 vs. 21.13%, respectively, p = 1.000). In univariate analysis, previous steroids, perianal CD, and stomas were considered risk factors for surgical complications, and previous steroids and hypoalbuminemia for medical complications. In multivariate analysis, previous steroids were associated with higher rates of surgical and medical complications, while hypoalbuminemia was associated with higher medical complication rates.
CONCLUSIONS: There was no influence of the previous use of anti-TNF agents in postoperative surgical and medical complication rates in elective intestinal resections for CD. Previous steroids and hypoalbuminemia were associated with higher complication rates. This was the first case series of the literature describing outcomes in exclusively elective operations.

Entities:  

Keywords:  Biological products; Crohn’s disease; Postoperative complications; Tumor necrosis factor alpha

Mesh:

Substances:

Year:  2016        PMID: 27933472     DOI: 10.1007/s10620-016-4400-2

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  24 in total

1.  The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management.

Authors:  A Dignass; G Van Assche; J O Lindsay; M Lémann; J Söderholm; J F Colombel; S Danese; A D'Hoore; M Gassull; F Gomollón; D W Hommes; P Michetti; C O'Morain; T Oresland; A Windsor; E F Stange; S P L Travis
Journal:  J Crohns Colitis       Date:  2010-01-15       Impact factor: 9.071

2.  A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

Authors:  S R Targan; S B Hanauer; S J van Deventer; L Mayer; D H Present; T Braakman; K L DeWoody; T F Schaible; P J Rutgeerts
Journal:  N Engl J Med       Date:  1997-10-09       Impact factor: 91.245

Review 3.  Preoperative infliximab use and postoperative complications in Crohn's disease: a systematic review and meta-analysis.

Authors:  Zhi-Ping Yang; Liu Hong; Qiong Wu; Kai-Chun Wu; Dai-Ming Fan
Journal:  Int J Surg       Date:  2014-01-03       Impact factor: 6.071

4.  The impact of preoperative anti-TNF in surgical and infectious complications of abdominal procedures for Crohn's disease: controversy still persists.

Authors:  Paulo Gustavo Kotze; Claudio Saddy Rodrigues Coy
Journal:  Am J Gastroenterol       Date:  2014-01       Impact factor: 10.864

5.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

6.  Biologic treatment or immunomodulation is not associated with postoperative anastomotic complications in abdominal surgery for Crohn's disease.

Authors:  Alaa El-Hussuna; Jens Andersen; Thue Bisgaard; Per Jess; Mads Henriksen; Jacob Oehlenschlager; Ole Thorlacius-Ussing; Gunnar Olaison
Journal:  Scand J Gastroenterol       Date:  2012-04-10       Impact factor: 2.423

7.  Effect of infliximab on the healing of intestinal anastomosis. An experimental study in rats.

Authors:  Ioannis Papaconstantinou; Christos Zeglinas; Maria Gazouli; Konstantinos Nastos; Anneza Yiallourou; Panagis Lykoudis; Konstantinos Evangelou; Apostolos Papalois; Marilena Papaioannou; John Vlachogiannakos; Charalampos Tzathas
Journal:  Int J Surg       Date:  2014-08-01       Impact factor: 6.071

8.  Effect of perioperative immunosuppressive medication on early outcome in Crohn's disease patients.

Authors:  Adrian A Indar; Tonia M Young-Fadok; Jacques Heppell; Jonathan E Efron
Journal:  World J Surg       Date:  2009-05       Impact factor: 3.352

9.  Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn's patients.

Authors:  Kweku A Appau; Victor W Fazio; Bo Shen; James M Church; Bret Lashner; Feza Remzi; Aaron Brzezinski; Scott A Strong; Jeffrey Hammel; Ravi P Kiran
Journal:  J Gastrointest Surg       Date:  2008-08-15       Impact factor: 3.452

10.  Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Abdominal Operations for Inflammatory Bowel Disease.

Authors:  Amy L Lightner; Laura E Raffals; Kellie L Mathis; Robert R Cima; Chung Sang Tse; John H Pemberton; Eric J Dozois; Edward V Loftus
Journal:  J Crohns Colitis       Date:  2016-08-19       Impact factor: 9.071

View more
  17 in total

1.  Risk factors for early postoperative complications and length of hospital stay in ileocecal resection and right hemicolectomy for Crohn's disease: a single-center experience.

Authors:  Christian Galata; Christel Weiss; Julia Hardt; Steffen Seyfried; Stefan Post; Peter Kienle; Karoline Horisberger
Journal:  Int J Colorectal Dis       Date:  2018-05-07       Impact factor: 2.571

2.  Effects of preoperative anti-tumour necrosis factor alpha infusion timing on postoperative surgical site infection in inflammatory bowel disease: A systematic review and meta-analysis.

Authors:  YuJie Qiu; ZiCheng Zheng; Gang Liu; XinYu Zhao; AnQi He
Journal:  United European Gastroenterol J       Date:  2019-09-30       Impact factor: 4.623

Review 3.  Association between preoperative tumor necrosis factor alpha inhibitor and surgical site infection after surgery for inflammatory bowel disease: a systematic review and meta-analysis.

Authors:  Motoi Uchino; Hiroki Ikeuchi; Junzo Shimizu; Hiroki Ohge; Seiji Haji; Toru Mizuguchi; Yasuhiko Mohri; Chizuru Yamashita; Yuichi Kitagawa; Katsunori Suzuki; Motomu Kobayashi; Masahiro Kobayashi; Fumie Sakamoto; Masahiro Yoshida; Toshihiko Mayumi; Koichi Hirata; Yoshio Takesue
Journal:  Surg Today       Date:  2020-04-10       Impact factor: 2.549

Review 4.  [Perioperative handling of immunosuppressive therapy].

Authors:  J Wagner; V Luber; J F Lock; U A Dietz; S Lichthardt; N Matthes; K Krajinovic; C-T Germer; S Knop; A Wiegering
Journal:  Chirurg       Date:  2018-02       Impact factor: 0.955

Review 5.  Prehabilitation prior to intestinal resection in Crohn's disease patients: An opinion review.

Authors:  Michiel T J Bak; Marit F E Ruiterkamp; Oddeke van Ruler; Marjo J E Campmans-Kuijpers; Bart C Bongers; Nico L U van Meeteren; C Janneke van der Woude; Laurents P S Stassen; Annemarie C de Vries
Journal:  World J Gastroenterol       Date:  2022-06-14       Impact factor: 5.374

6.  Compare risk factors associated with postoperative infectious complication in Crohn's disease with and without preoperative infliximab therapy: a cohort study.

Authors:  Shasha Tang; Xue Dong; Wei Liu; Weilin Qi; Lingna Ye; Xiaoyan Yang; Qian Cao; Xiaolong Ge; Wei Zhou
Journal:  Int J Colorectal Dis       Date:  2020-02-14       Impact factor: 2.571

Review 7.  Reducing Perioperative Risks of Surgery in Crohn's Disease.

Authors:  Wolfgang Reindl; Anne Kerstin Thomann; Christian Galata; Peter Kienle
Journal:  Visc Med       Date:  2019-11-12

8.  Increased Risk of Infections with Anti-TNF Agents in Patients with Crohn's Disease After Elective Surgery: Meta-Analysis.

Authors:  Jurij Hanzel; Ahmed Almradi; Alexandra C Istl; Mei Lucy Yang; Katherine A Fleshner; Claire E Parker; Leonardo Guizzetti; Christopher Ma; Siddharth Singh; Vipul Jairath
Journal:  Dig Dis Sci       Date:  2021-02-26       Impact factor: 3.199

9.  Comparison of time until elective intestinal resection regarding previous anti-tumor necrosis factor exposure: a Brazilian study on patients with Crohn's disease.

Authors:  Paulo Gustavo Kotze; Daniela Oliveira Magro; Barbara Saab; Mansur Paulo Saab; Lilian Vital Pinheiro; Marcia Olandoski; Maria de Lourdes Setsuko Ayrizono; Carlos Augusto Real Martinez; Claudio Saddy Rodrigues Coy
Journal:  Intest Res       Date:  2018-01-18

10.  Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease.

Authors:  Cindy Cy Law; Conor Bell; Deborah Koh; Yueyang Bao; Vipul Jairath; Neeraj Narula
Journal:  Cochrane Database Syst Rev       Date:  2020-10-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.